Close
Kate Lathrop, M.D.
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Kate Lathrop, M.D.
Dr. Lathrop was named one of San Antonio’s Top Doctors for Women and San Antonio’s Top Doctors 2021.
Gender
- Female
-
Credentials
Credentials
Certifications
- American Board of Internal Medicine/Medical Oncology
- American Board of Internal Medicine
Education
- Medical School: University of Texas Health Science Center at San Antonio
- Residency: University of Texas Health Science Center at San Antonio
-
Locations & Contact
Locations & Contact
Dr. Lathrop is terrific. She listens and explains. I always feel very confident that I got the best care possible.
Patient
-
Research & Publications
Research & Publications
Breast Cancer Treatment Delays in a Majority Minority Community: Is There a Difference?
Parsons, H. M., Lathrop, K. I., Schmidt, S., Mazo-Canola, M., Trevino-Jones, J., Speck, H. & Karnad, A. B.
J. Oncol. Pract. 11(2):e144-53 (2014). PMID: 25515722; PMCID: PMC4365298
Use of Milestones and Development of Entrustable Professional Activities in 2 Hematology/ Oncology Training Programs.
Shumway, N. M., Dacus, J. J., Lathrop, K. I., Hernandez, E. P., Miller, M. & Karnad, A. B.
J. Grad. Med. Educ. 7, 101-104 (2015). PMID: 26217433; PMCID: PMC4507897
-
Clinical Trials
Clinical Trials
ClinicalTrials.gov Identifier
NCT02003209
Principal Investigator
Kate Lathrop M.D.
NSABP-B-52, A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin,
This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab with estrogen deprivation to see how they work compared to docetaxel, carboplatin, trastuzumab, and pertuzumab without estrogen deprivation in treating patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer that is operable or has spread from where…
Type of Cancer
Breast
ClinicalTrials.gov Identifier
NCT01674140
Principal Investigator
Kate Lathrop M.D.
S1207, Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (CTRC# 13-0002)
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone…
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Kate Lathrop M.D.
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer. CTMS# 18-0085